Table 4 TLC and HPTLC methods for analysis of FDA-approved treatments for several cardiovascular illnesses from 2015 to June 2020
Stationary phase | Mobile phase (v/v) | Detection (nm) | Applications |
|---|---|---|---|
Silica gel 60GF254 | Glacial acetic acid: Ethyl acetate: Methanol: (0.1:9:1) | 260 | Estimation of sacubitril and valsartan in pharmaceutical dosage forms (Alamein 2018) |
Silica gel 60F254 (TLC) | Toulene:Ethylacetate:Methanol(4:4:2) | 260 | Determination of sacubitril and valsartan by densitometry (Khalid et al. 2018) |
Silica gel 60GF254 | Ethylacetate:0.389 m ammonium acetate in methanol (1:5) | 287 | Determination of ivabradine in bulk and marketed formulation (Motisariya et al. 2013) |
Silica gel 60GF254 | Methanol:Chlorofrom:Water (8:1:1) | 286 | Stability indicating chromatographic method of ivabradine (Damle and Bagwe 2015) |
Silica gel 60GF254 | Toulene:Methanol:Triethylamine(7.5:1:0.2) | 230 | Determination of edoxaban in bulk and marketed formulation (Dhiware et al. 2019) |